UNSPSC 51131506: Erythropoietin

This classification denotes a chemotherapy regimen used to treat non-hodgkins lymphoma with the molecular formula C809H1301N229O240S5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64FS3BFH5W, more generally known as erythropoietin. European Medicines Agency schedules erythropoietin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06575MIG. The term ERYTHROPOIETIN is an International Non-Proprietary Name or INN. As of Q4 2014, ERYTHROPOIETIN remains the US FDA Preferred Term for this commodity.

Erythropoietin bears US NLM identifiers UMLS ID C0014822 and NCI Concept Code C20429. SMILES: NONE.

UNSPSC 51131506 Erythropoietin, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The single recent opportunity tagged to this code is Sourcewell RFP #061626, posted May 12, 2026 with a response deadline of June 16, 2026 at 3:30 p.m. Central Time, which solicits law enforcement equipment on behalf of participating entities across Washington state and other jurisdictions — a category plainly unrelated to pharmaceutical erythropoietin products. No state or local opportunities for erythropoietin or related hematologic therapies appear in the recent record, suggesting either minimal purchasing activity under this code or systematic miscoding in the state and local procurement notices.

The law enforcement equipment solicitation is structured as a cooperative purchasing contract through Sourcewell, a Minnesota local government unit, and is open to participating governmental agencies, school districts, higher education institutions, tribal governments, and nonprofit organizations across the United States and Canada. Responses must be submitted exclusively through the Sourcewell Procurement Portal at https://proportal.sourcewell-mn.gov. Given the absence of erythropoietin-specific opportunities in state and local procurement pipelines, firms pursuing pharmaceutical or blood-therapy contracting should verify their UNSPSC coding against actual solicitation language rather than relying on code number alone.